-
The Investigational New Drug (IND) is open for all Phase 3 studies
-
Phase 2 trials are completed without any safety or tolerability concerns
-
Positioned to be the first registered oral monotherapy treatment for Treatment Resistant Depression
-
R-107 will shift the treatment paradigm, utilizing convenient at-home, self-administration for a safe, rapid and durable reduction of depressive symptoms
Introducing R-107
R-107 is in late-stage clinical development with a regulatory pathway aligned with the expectations of the US FDA and Scientific Advice from EU Member States. The Investigational New Drug (IND) is open with the FDA for all Phase 3 studies.
The pharmacokinetics of R-107's timed delivery system provides for a safe, robust antidepressant effect without dissociation of clinical significance.
Douglas Pharmaceuticals, of which Tasman Therapeutics is a wholly owned subsidiary, has patents granted and pending to protect these unique features as well as the dose regimen until at least 2037 with applications pending with potential expiration >2045.
About us
Tasman Therapeutics is a newly incorporated, US-based subsidiary of Douglas Pharmaceuticals Ltd, New Zealand’s largest pharmaceutical company. Founded in 1967, Douglas products are available in 40 countries with branded, complex generic, and 505(b)(2) formulations.
Headquartered in the San Francisco Bay Area, Tasman Therapeutics is headed up by an accomplished team of industry professionals, who between them have:
-
>250 published research papers and chapters
-
>50 clinical stage programs completed
-
>10 commercialized products in the US & EU
-
Demonstrated expertise in developing first-in world generics and novel products.
Our executive team
_edited.jpg)
_edited.jpg)
_edited_edited.png)
R-107 Clinical Advisory Board Members
Prof. Paul Glue, MB, ChB (Otago), MD (Bristol), FRCPsych
Dr. Paul Glue is the Hazel Buckland Professor of Psychiatry at the University of Otago, New Zealand and Chair of Douglas’ R-107 Clinical Advisory Board.
He joins in the role of Board Chair with extensive experience in psychiatric research, including early development of R-107. He has published extensively in the fields above, with more than 250 papers and book chapters to his name.
Investors
-
We seek strategic investors to advance this critical innovation. With your support, we aim to bring hope to millions and capture a substantial share of this growing market.
-
Complete the form below to receive our Investor Information pack by email straight away.
The R-107 Advantage
Platform
-
A novel proprietary oral technology to safely deliver ketamine for the treatment of mood disorders by modulating GABA and glutamate neurotransmitters instead of monoamines.
-
Tasman has overcome a long-standing hypothesis that a significant dissociation is required to trigger a rapid anti-depressant response in patients with hard-to-treat clinical depression.
-
Tasman has also established the minimum effective oral dose associated with this novel “timed” oral delivery of ketamine.
Product
-
A tablet that delivers ketamine at a slow steady rate to achieve a rapid, robust and durable antidepressant response without dissociation of significance, enabling a pathway to safe at-home administration.
-
The controlled release of ketamine from R-107 also reduces addiction potential compared to more rapidly delivered ketamine dosage forms.
-
Results of a Phase 2 dose finding trial treating 231 patients with treatment resistant depression were published late last year in Nature Medicine. This study included patients on ketamine monotherapy and with concomitant medications, and was effective in both groups. Patients self-administered R-107 at home with no safety concerns and >96% compliance on investigational product.
Market
-
Tens of millions still suffer from failure of existing medical treatment to treat their depression.
-
Around one third of patients fail two or more first line treatments such as SSRI/SNRI’s or combination therapies with antipsychotics.
-
An oral new mode of action treatment not restricted to in-clinic administration provides accessibility for patients, improves patient compliance, and reduces burden on HCP’s.
Tasman and Douglas
Tasman Therapeutics, Inc. is a US subsidiary of New Zealand-based Douglas Pharmaceuticals Ltd with a pipeline developing novel treatments for mood disorders. The most advanced asset is R-107, a proprietary ketamine oral dose in Phase 3 studies as a therapy for patients with hard-to-treat depression.
Douglas Pharmaceuticals develops and supplies generic and repurposed medicines to the US, EU and global markets. R-107 is manufactured at its US FDA inspected plant in Auckland, New Zealand.
News
News
News
Articles
Long Term Safety and Efficacy of Oral Extended-Release Ketamine: Results from the Bedroc-1 Study
Cell Reports Medicine (Under peer-review, pre-print)
Published: Mar 24, 2025
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Published: May 8, 2024
Influence of formulation and route of administration on ketamine’s safety and tolerability: systematic review
European Journal of Clinical Pharmacology
Published: 18 Nov, 2020
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study
Therapeutic Advances in Psychopharmacology
Published: Jan 2020
Ascending-Dose Study of Controlled-Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability
The Journal of Clinical Pharmacology
Published: 17 Feb, 2020
